Blackstone (BX) is experiencing varied market reactions, with discernible
share price volatility lately. Some analysts are pondering how low it might sink during a market crash, while others see a stock sitting 45% below its highs with potential for rebounding. There have been
investor movements, such as F m Investments LLC purchasing over 24,000 shares, and Capital Research Global Investors buying over 20,000 shares. Reactions to BX's stock price are mixed and are driven by factors including
valuation recalibrations,
JPMorgan's credit restrictions, and the overall sector anxiety.
Blackstone's activities include committing $400 million with Teva to advance Duvakitug clinical development and acquiring a majority stake in pressure cooling firm. They're also looking to partner with Anthropic for consulting services. Major institutions
Barclays and
JPMorgan both cut their price target on BX, which has led to some bearish sentiment. However,
RBC Capital initiated Blackstone's coverage with a $179 target based on a strong growth outlook. This mixed bag of influences underscores the uncertainty in BX's current market standing, yet intriguing potential for future positioning.
Blackstone BX News Analytics from Thu, 23 Oct 2025 07:00:00 GMT to Sat, 14 Mar 2026 19:21:44 GMT -
Rating 3
- Innovation 4
- Information 8
- Rumor -6
